Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Abeona Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding Abeona Therapeutics Inc.’s stock price such as:

• Abeona Therapeutics Inc.’s current stock price and volume
• Why Abeona Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for ABEO from analysts
• ABEO’s stock price momentum as measured by its relative strength

About Abeona Therapeutics Inc. (ABEO)

Before we jump into Abeona Therapeutics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Want to learn more about Abeona Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Abeona Therapeutics Inc..

Abeona Therapeutics Inc.’s Stock Price as of Market Close

As of May 08, 2026, 11:30 AM, CST, Abeona Therapeutics Inc.’s stock price was $5.875.

Abeona Therapeutics Inc. is up 1.82% from its previous closing price of $5.770.

During the last market session, Abeona Therapeutics Inc.’s stock traded between $5.740 and $5.960. Currently, there are approximately 55.22 million shares outstanding for Abeona Therapeutics Inc..

Abeona Therapeutics Inc.’s price-earnings (P/E) ratio is currently at 5.7, which is low compared to the Biotechnology industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Abeona Therapeutics Inc. Stock Price History

Abeona Therapeutics Inc.’s (ABEO) price is currently up 7.6% so far this month.

During the month of May, Abeona Therapeutics Inc.’s stock price has reached a high of $6.070 and a low of $5.400.

Over the last year, Abeona Therapeutics Inc. has hit prices as high as $7.540 and as low as $4.000. Year to date, Abeona Therapeutics Inc.’s stock is up 11.48%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Abeona Therapeutics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 0 analysts who downgraded Abeona Therapeutics Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Abeona Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Abeona Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Abeona Therapeutics Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Abeona Therapeutics Inc. (ABEO) by visiting AAII Stock Evaluator.

Relative Price Strength of Abeona Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, Abeona Therapeutics Inc. has a weighted four-quarter relative price strength of -0.32%, which translates to a Momentum Score of 57 and is considered to be Average.

Want to learn more about how Abeona Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Abeona Therapeutics Inc. Stock Price: Bottom Line

As of May 8, 2026, Abeona Therapeutics Inc.’s stock price is $5.875, which is up 1.82% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Abeona Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.